Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04465864 · ClinicalTrials.gov registry record · Phase 4

Investigate, Following Cataract Surgery With IOL in Conjunction With Intracanalicular Dexamethasone Insert

A Phase 4 study of Cataract and Glaucoma, Primary Open Angle, sponsored by Wolstan and Goldberg Eye Associates.

Completed
Registry status
Phase 4
Development phase
40
Enrollment target
1
Study location

NCT04465864 is a Phase 4 study of Cataract and Glaucoma, Primary Open Angle that has completed, run by Wolstan and Goldberg Eye Associates. The registered enrollment target is 40 participants, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04465864, a Phase 4 study of Cataract and Glaucoma, Primary Open Angle, has completed, sponsored by Wolstan and Goldberg Eye Associates.

COMPLETED
Registry status
Phase 4
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

Randomized, controlled treatment with an intracanalicular dexamethasone (0.4mg) insert following cataract surgery with intraocular lens implant (IOL) combined with minimally invasive glaucoma surgery (MIGS), specifically iStent, iStent inject or KDB in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHTN)

Interventions

  • DRUG Intracanalicular Dexamethasone, 0.4 mg insert

Study Locations (1)

California

  • Wolstan and Goldberg Eye Associates - Torrance

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2020-02-10
Est. Completion 2021-01-31
Phase Phase 4

What the Registry Record Tells You About NCT04465864

The ClinicalTrials.gov registry entry for NCT04465864 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (82% lower). The listed sponsor is Wolstan and Goldberg Eye Associates, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cataract appearing as the primary indexed condition, and to 1 intervention - of which Intracanalicular Dexamethasone, 0.4 mg insert is the first listed.

NCT04465864 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04465864 about?

NCT04465864 is a clinical study titled "Investigate, Following Cataract Surgery With IOL in Conjunction With Intracanalicular Dexamethasone Insert". Randomized, controlled treatment with an intracanalicular dexamethasone (0.4mg) insert following cataract surgery with intraocular lens implant (IOL) combined with minimally invasive glaucoma surgery (MIGS), specifically iStent, iStent inject or KDB in patients with primary open angle glaucoma (POAG...

What is the current status of trial NCT04465864?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2020-02-10. Estimated completion is 2021-01-31.

What conditions does trial NCT04465864 study?

This clinical trial studies the following conditions: Cataract, Glaucoma, Primary Open Angle.

What interventions are being tested in trial NCT04465864?

The interventions under investigation include: Intracanalicular Dexamethasone, 0.4 mg insert (DRUG).

Who is sponsoring clinical trial NCT04465864?

This trial is sponsored by Wolstan and Goldberg Eye Associates, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04465864 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cataract

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.